Hepatitis C Treatments/Therapies | Hepatitis Central - Part 31

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Hepatitis C Treatments/Therapies

How Fatty Acid Metabolism May Stop the Hepatitis C Virus

Oct 7, 2008

On September 28, 2008, researchers announced study results showing a new way to reduce viral replication (the progression of viral infection). The liver disease Hepatitis C may be chosen as a candidate for further exploration in this new technique to inhibit viral replication. For their study, the scientists had experimented with the herpes virus and fatty acid metabolism, and believe they can use existing drugs to inhibit viral replication in a number of diseases, including Hepatitis C. To learn why scientists are considering Hepatitis C as one of the candidates for further exploration of this unique way of metabolically blocking viral replication, read this article.

Continue reading »

Hepatitis C Study Increases Interest in SCV-07

Sep 26, 2008

Trial results show SciClone's SCV-07 effectively reduces Hepatitis C viral load in previous non-responders with genotype 1. Based on these encouraging results, a follow-up study to evaluate SCV-07's potential to replace or improve the current Hepatitis C standard treatment will unfold next year.

Continue reading »

New Hope for HCV

Sep 22, 2008

Funded by Pfizer, Tacere's licensed RNAi technology could change the way Hepatitis C is treated. A mechanism that inhibits genes from transferring information and creating new genetic material, RNAi-based drugs may be able to silence the genes that cause disease.

Continue reading »

HCV Genotype 1 Viral Loads Decline

Sep 5, 2008

A six-month follow-up to Intercell's Phase II trial of their Hepatitis C vaccine with a topical toll-like receptor agonist showed a significant reduction in viral load. While data from two weeks after the vaccination series showed promise, participants with Hepatitis C genotype 1 had viral loads that continued to decline six months after treatment.

Continue reading »

Anadys' ANA773 Hepatitis C Phase I Trials in Netherlands

Jul 9, 2008

Reducing the dosing schedule in half, Anadys Pharmaceuticals continues its investigation of ANA773, a Toll-Like Receptor-7 agonist prodrug. Approaching the Hepatitis C virus differently from most other contenders, Phase I clinical trials evaluating the safety, tolerability and viral-load decline associated with ANA773 are about to begin in the Netherlands.

Continue reading »